Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
517 participants
OBSERVATIONAL
2014-09-30
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators evaluated the contribution of serum biomarkers levels to the pathogenesis of coronary artery disease, namely their association with risk factors, clinical presentation, extent and severity of atherosclerotic changes accompanying coronary artery disease.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Early Detection of Arteriosclerosis
NCT00863967
Identification of New Biomarkers for the Prediction of Cardiovascular Events
NCT04809506
Cardiovascular Risk Factors, Lipid Metabolism and Oxidative Stress
NCT01213303
Risk Factors of Individuals With Coronary Artery Disease
NCT00260104
Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)
NCT06122961
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Healthy subjects
\- 207 healthy subjects were donors,(33.2±12.2 years) recruited from the Blood Bank Department of the University Hospital (Mahdia, Tunisia).
Patients
\- 310 subjects with CAD (60.3±11.0 years) were admitted to the Department of Cardiology, University Hospital (Monastir, Tunisia).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Liver disease
* kidney disease
* Inflammatory diseases (infections, autoimmune disorders, malignancy).
20 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nadia Bouzidi, PhD
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nadia Bouzidi, PhD
Bouzidi Nadia, PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Salima Ferchichi, Pr
Role: STUDY_DIRECTOR
University of Monastir, Faculty of Pharmacy of Monastir, Tunisia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Pharmacy
Monastir, Ibn Sina Street, Tunisia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Bouzidi N, Gamra H. Relationship between serum interleukin-6 levels and severity of coronary artery disease undergoing percutaneous coronary intervention. BMC Cardiovasc Disord. 2023 Nov 28;23(1):586. doi: 10.1186/s12872-023-03570-8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1500170
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.